Bbva Compass Bancshares Inc. cut its position in Medtronic PLC (NYSE:MDT) by 1.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 88,357 shares of the medical technology company’s stock after selling 1,280 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Medtronic were worth $8,047,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of MDT. Oregon Public Employees Retirement Fund raised its holdings in shares of Medtronic by 8,884.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,286,072 shares of the medical technology company’s stock valued at $146,000 after purchasing an additional 13,138,192 shares during the last quarter. Norges Bank purchased a new position in shares of Medtronic during the fourth quarter valued at approximately $1,120,279,000. American Century Companies Inc. raised its holdings in shares of Medtronic by 23.0% during the fourth quarter. American Century Companies Inc. now owns 9,746,733 shares of the medical technology company’s stock valued at $886,563,000 after purchasing an additional 1,821,093 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Medtronic by 10.2% during the fourth quarter. Geode Capital Management LLC now owns 16,690,207 shares of the medical technology company’s stock valued at $1,515,557,000 after purchasing an additional 1,538,130 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Medtronic by 242.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,150,823 shares of the medical technology company’s stock valued at $195,639,000 after purchasing an additional 1,523,109 shares during the last quarter. 81.52% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE MDT opened at $87.73 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.36 and a quick ratio of 1.92. The company has a market cap of $117.66 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 2.18 and a beta of 0.78. Medtronic PLC has a 12-month low of $81.66 and a 12-month high of $100.15.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 19th. The medical technology company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.05. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 16.10% and a return on equity of 13.85%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.17 earnings per share. Equities research analysts anticipate that Medtronic PLC will post 5.15 EPS for the current year.

MDT has been the subject of several research reports. Zacks Investment Research cut shares of Medtronic from a “hold” rating to a “sell” rating in a report on Tuesday, April 30th. Wells Fargo & Co decreased their price objective on shares of Medtronic from $101.00 to $100.00 and set a “market perform” rating for the company in a report on Thursday, April 4th. Needham & Company LLC reissued a “strong-buy” rating and set a $117.00 price objective (down from $120.00) on shares of Medtronic in a report on Monday, February 4th. Oppenheimer set a $104.00 price objective on shares of Medtronic and gave the company a “buy” rating in a report on Wednesday, February 20th. Finally, Northland Securities reissued a “hold” rating and set a $84.00 price objective on shares of Medtronic in a report on Monday, March 18th. One analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $103.39.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2019/05/20/medtronic-plc-mdt-holdings-cut-by-bbva-compass-bancshares-inc.html.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Read More: Earnings Per Share

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.